Author: admin

Pfizer on Tuesday said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharmaceutical company’s push into the weight loss space. 

Pfizer will pay YaoPharma, a subsidiary of Chinese drugmaker Shanghai Fosun Pharmaceutical, an upfront payment of $150 million. YaoPharma could also receive up to $1.94 billion in milestone payments, along with tiered royalties on sales if the drug is approved. 

YaoPharma’s drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk‘s blockbuster weight loss injection Wegovy. But the pill is still in early-stage development, which means it will take several years before it reaches patients. 

The deal will help Pfizer beef up and diversify its obesity drug pipeline after a string of setbacks, including its decisions to scrap two different pills over the last two years. The drugmaker boosted its prospects in the competitive space with its up to $10 billion acquisition of the obesity biotech Metsera last month, following a fierce bidding war with Novo Nordisk. 

“We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity and its adjacent diseases,” said Chris Boshoff, Pfizer’s chief scientific officer, in a statement. 

Under the terms of the agreement, YaoPharma will conduct a phase one trial on its drug, while Pfizer will take control of later development. Pfizer also plans to conduct studies combining YaoPharma’s treatment with its own drug targeting another gut hormone receptor called GIP, which is currently in mid-stage development.

That combination isn’t new in the space: Eli Lilly‘s weight loss injection Zepbound and diabetes drug Mounjaro use a dual approach of targeting both GLP-1 and GIP. 

In a note on Tuesday, BMO Capital Markets analyst Evan Seigerman said limited information is available on YaoPharma’s drug, called YP05002. But Seigerman said he views “obesity diversification as promising in the short term” for Pfizer. 

He added that Pfizer’s $150 million upfront payment reflects “prudent capital conservation in light of the recent Metsera bidding war.”

The opportunity to enter the booming weight loss drug market could be huge for Pfizer. Some analysts expect the weight loss drug space could be worth roughly $100 billion by the 2030s.